AMG 701 demonstrated antitumor activity in mouse xenograft models. (A) Tumor volumes of NOD/SCID mice injected subcutaneously with a mixture of NCI-H929 tumor cells and human PBMCs (1:2 E:T ratio) and treated with vehicle or AMG 701 (2, 0.2, and 0.02 mg/kg) on days 3, 8, and 13. Data are mean ± standard error of the mean (SEM) (n = 5, vehicle group; n = 10, all other groups). P < .001 for all dose levels from day 10 until day 23 vs vehicle + PBMC group, 1-way ANOVA with the Dunnett post hoc test. (B) PK profile of AMG 701 in mouse serum at the times indicated after the last administration on day 13. Data are mean ± SEM (n = 3). (C) Kaplan-Meier survival analysis of NOD/SCID mice orthotopically transplanted with L-363 MM cells, injected intraperitoneally with human T cells on day 5 (except for vehicle-only control), and treated with AMG 701 (0.5, 0.05, and 0.005 mg/kg) or vehicle every 5 days for 6 administrations, starting on day 9. Arrows indicate days of treatment (n = 5, vehicle group; n = 10, all other groups). **P = .007, ***P < .001 vs vehicle + T-cell group, Kaplan-Meier estimator with Mantel-Cox log-rank test. (D) Tumor volumes of SCID mice injected subcutaneously with NCI-H929 tumor cells (5E6) on day 1, intraperitoneally injected with human T cells (1.2E7) on day 8, and treated with vehicle or AMG 701 (0.25, 0.05, or 0.01 mg/kg) on days 15 and 22. Data are mean ± SEM (n = 5, vehicle group; n = 8, all other groups). ****P < .0001, ***P = .0002, 1-way ANOVA with the Dunnett post hoc test.